Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Initiation of Translation02:33

Initiation of Translation

39.0K
Initiating translation is complex because it involves multiple molecules. Initiator tRNA, ribosomal subunits, and eukaryotic initiation factors (eIFs) are all required to assemble on the initiation codon of mRNA. This process consists of several steps that are mediated by different eIFs.
First, the initiator tRNA must be selected from the pool of elongator tRNAs by eukaryotic initiation factor 2 (eIF2). The initiator tRNA (Met-tRNAi) has conserved sequence elements including modified bases at...
39.0K
Initiation of Translation02:33

Initiation of Translation

8.1K
8.1K
Transcription Initiation01:47

Transcription Initiation

21.1K
Initiation is the first step of transcription in eukaryotes. Prokaryotic RNA Polymerase (RNAP) can bind to the template DNA and start transcribing. On the other hand, transcription in eukaryotes requires additional proteins, called transcription factors, to first bind to the promoter region in the DNA template. This binding helps recruit the specific RNAP that can assemble on the DNA and start transcription.
The promoters and enhancers and their accessory proteins allow tight regulation of...
21.1K
Gene Therapy00:59

Gene Therapy

27.6K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
27.6K
Optimal Foraging00:48

Optimal Foraging

13.8K
How animals obtain and eat their food is called foraging behavior. Foraging can include searching for plants and hunting for prey and depends on the species and environment.
13.8K
S-Cdk Initiates DNA Replication02:38

S-Cdk Initiates DNA Replication

5.7K
The cell cycle is a series of events leading to DNA duplication followed by the division of cell content to form two daughter cells. The cell cycle progresses in four stages—the cell increases in size (gap 1 or G1-phase), duplicates its DNA (synthesis or S-phase), prepares to divide (gap 2 or G2-phase), and divides (mitosis or M-phase).
Two states at the origin of replication
In eukaryotes, the initiation of replication occurs at many sites on the chromosomes, called the origins of...
5.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Short ramp-up glofitamab halves mortality risk after anti-CD19 CAR T-cell therapy failure in patients with diffuse large B-cell lymphoma: final results of the LYSA BiCAR phase 2 trial with a pre-specified external control arm.

Journal of hematology & oncology·2026
Same author

Role of radiotherapy in refractory/relapsed classical Hodgkin lymphoma in the era of targeted therapies and immunotherapy.

Clinical and translational radiation oncology·2026
Same author

Epcoritamab monotherapy or epcoritamab with lenalidomide as first-line therapy for patients with diffuse large B-cell lymphoma (EPCORE DLBCL-3): primary analysis of an open-label, multicentre, randomised, phase 2 trial.

The Lancet. Haematology·2026
Same author

Outcomes of critically ill patients with newly diagnosed Burkitt's lymphoma: a monocentric retrospective study.

Annals of intensive care·2026
Same author

Integrated multi-omic profiling reveals two distinct splenic marginal zone lymphoma subgroups with prognostic relevance.

Blood advances·2026
Same author

Prolonged survival with glofitamab in non-diffuse large B-cell lymphoma after CAR T-cell therapy relapse.

Haematologica·2026
Same journal

CAR-T cell therapy for multiple myeloma: An update on the current state and future potential.

Best practice & research. Clinical haematology·2025
Same journal

Cancer vaccines in hematologic malignancy: A systematic review of the rational and evidence for clinical use.

Best practice & research. Clinical haematology·2025
Same journal

Immune therapy of haematological cancers.

Best practice & research. Clinical haematology·2025
Same journal

Advances in NK cell therapy for multiple myeloma.

Best practice & research. Clinical haematology·2025
Same journal

Adoptive cellular therapies in multiple myeloma.

Best practice & research. Clinical haematology·2025
Same journal

Bispecific T-cell engager therapy for multiple myeloma.

Best practice & research. Clinical haematology·2025
See all related articles

Related Experiment Video

Updated: Feb 5, 2026

Simultaneous Imaging and Flow-Cytometry-based Detection of Multiple Fluorescent Senescence Markers in Therapy-Induced Senescent Cancer Cells
08:56

Simultaneous Imaging and Flow-Cytometry-based Detection of Multiple Fluorescent Senescence Markers in Therapy-Induced Senescent Cancer Cells

Published on: July 12, 2022

3.5K

Optimizing initial therapy in DLBCL.

Catherine Thieblemont1, Sophie Bernard1, Michel Meignan2

  • 1APHP, Saint-Louis Hospital, Hemato-Oncology, 4, Avenue Claude Vellefaux, 75010, Paris, France; Diderot University, Sorbonne Paris-Cité, Paris, France, 10 Avenue de Verdun, 75010, Paris, France; EA7324, Descartes University, 4 Avenue de l'Observatoire, 75006, Paris, France.

Best Practice & Research. Clinical Haematology
|September 15, 2018
PubMed
Summary
This summary is machine-generated.

Optimizing initial therapy for diffuse large B-cell lymphoma (DLBCL) involves identifying high-risk subtypes using biomarkers and imaging. Novel drug combinations and central nervous system (CNS) prophylaxis are crucial for improving treatment outcomes in DLBCL patients.

Keywords:
CNS prophylaxisDiffuse large B-cell lymphomaPrognostic factorsR-CHOPTMTV

More Related Videos

Analysis of Translation Initiation During Stress Conditions by Polysome Profiling
10:59

Analysis of Translation Initiation During Stress Conditions by Polysome Profiling

Published on: May 19, 2014

18.9K
Chuzhen Therapy as a Non-Invasive Traditional Chinese Therapy for Neck Pain
04:24

Chuzhen Therapy as a Non-Invasive Traditional Chinese Therapy for Neck Pain

Published on: June 6, 2025

1.3K

Related Experiment Videos

Last Updated: Feb 5, 2026

Simultaneous Imaging and Flow-Cytometry-based Detection of Multiple Fluorescent Senescence Markers in Therapy-Induced Senescent Cancer Cells
08:56

Simultaneous Imaging and Flow-Cytometry-based Detection of Multiple Fluorescent Senescence Markers in Therapy-Induced Senescent Cancer Cells

Published on: July 12, 2022

3.5K
Analysis of Translation Initiation During Stress Conditions by Polysome Profiling
10:59

Analysis of Translation Initiation During Stress Conditions by Polysome Profiling

Published on: May 19, 2014

18.9K
Chuzhen Therapy as a Non-Invasive Traditional Chinese Therapy for Neck Pain
04:24

Chuzhen Therapy as a Non-Invasive Traditional Chinese Therapy for Neck Pain

Published on: June 6, 2025

1.3K

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Diffuse large B-cell lymphoma (DLBCL) presents heterogeneous subtypes with variable clinical outcomes.
  • The standard R-CHOP regimen shows high treatment failure rates in specific DLBCL subsets.
  • There is a critical need to optimize initial DLBCL therapy.

Purpose of the Study:

  • To review strategies for optimizing initial diffuse large B-cell lymphoma (DLBCL) therapy.
  • To discuss the role of biomarkers and imaging in personalizing treatment decisions.
  • To explore novel therapeutic approaches and CNS relapse prophylaxis for DLBCL.

Main Methods:

  • Review of current literature on DLBCL treatment optimization.
  • Analysis of biomarkers (e.g., MYC/BCL2 translocations, protein overexpression) and functional imaging.
  • Evaluation of dose-intensification strategies and novel drug additions to R-CHOP.
  • Examination of central nervous system (CNS) relapse prophylaxis in DLBCL.

Main Results:

  • Biomarkers like double-hit status and MYC/BCL2 overexpression help define high-risk DLBCL subsets.
  • Functional imaging can aid in risk stratification and treatment personalization.
  • Novel agents added to R-CHOP show promise for induction or maintenance therapy.
  • CNS relapse remains a significant unmet need, requiring further research in prophylaxis.

Conclusions:

  • Personalized treatment strategies incorporating biomarkers and imaging are essential for improving DLBCL outcomes.
  • Investigating dose-intensification and novel drug combinations is critical.
  • Developing effective CNS prophylaxis is a priority for managing DLBCL patients and preventing relapse.